ProShare Advisors
DFTX icon

ProShare Advisors’s Definium Therapeutics DFTX Stock Holding History

ProShare Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$775K Sell
20,366
-249
-1% -$10.5K ﹤0.01% 826
2026
Q2 		$970K Buy
20,615
+1,884
+10% +$46.6K ﹤0.01% 814
2026
Q1 		$354K Sell
18,731
-2,808
-13% -$47.7K ﹤0.01% 1253
2025
Q4 		$288K Buy
21,539
+5,947
+38% +$73.6K ﹤0.01% 1483
2025
Q3 		$184K Sell
15,592
-2,676
-15% -$25K ﹤0.01% 1710
2025
Q2 		$119K Sell
18,268
-941
-5% -$6.19K ﹤0.01% 1846
2025
Q1 		$112K Sell
19,209
-6,958
-27% -$49.8K ﹤0.01% 1813
2024
Q4 		$182K Buy
26,167
+12,562
+92% +$86.4K ﹤0.01% 1914
2024
Q3 		$77.4K Buy
+13,605
New +$94.6K ﹤0.01% 1922
2022
Q2 		– Sell
-4,026
Closed -$67K – 1995
2022
Q1 		$67K Sell
4,026
-1,041
-21% -$18.1K ﹤0.01% 2089
2021
Q4 		$105K Buy
5,067
+2,094
+70% +$66.8K ﹤0.01% 2196
2021
Q3 		$104K Sell
2,973
-2,597
-47% -$112K ﹤0.01% 1909
2021
Q2 		$288K Buy
+5,570
New +$292K ﹤0.01% 1923

Other funds holding DFTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

ProShare Advisors's DFTX Position: Q3 2026 in Review

ProShare Advisors reduced its Definium Therapeutics (DFTX) stake by 1.2% in Q3 2026, selling an estimated $10.5K and leaving 20,366 shares worth $775K. The position accounts for ﹤0.01% of the portfolio, ranked #826.

ProShare Advisors first reported a position in DFTX in Q2 2021 and has held it in 13 quarters since. The position peaked at $970K in Q2 2026. 139 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • ProShare Advisors held 20,366 shares of Definium Therapeutics worth $775K as of Q3 2026.
  • ProShare Advisors sold 249 Definium Therapeutics shares in Q3 2026, an estimated $10.5K.
  • Definium Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q3 2026, its #826 holding.
  • ProShare Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • ProShare Advisors's Definium Therapeutics position peaked at $970K in Q2 2026.
  • 139 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on ProShare Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.